MGI(SH:688114) Nan Fang Du Shi Bao·2026-02-01 14:20Core Viewpoint - The acquisition of 100% equity in Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. by the company for approximately 366 million yuan aims to integrate cutting-edge technologies into its operations, establishing a unique competitive advantage in the global life sciences sector [1][3]. Group 1: Acquisition Details - The total transaction price for the acquisition is approximately 366 million yuan [1]. - The acquisition will allow the company to incorporate spatial omics and nanopore sequencing technologies into its product offerings, making it the only global enterprise to cover the entire product matrix of "long-read sequencing + spatial omics" [3]. - The integration will enable the company to provide a one-stop service from library construction, sequencing to data analysis, enhancing customer service capabilities and stickiness [3][5]. Group 2: Strategic Value - The acquisition is strategically significant as it connects short-read (DNBSEQ), long-read (CycloneSEQ), and spatial omics technologies, creating a comprehensive technical chain that is difficult for competitors to replicate [3]. - The spatial omics technology can provide precise navigation for brain-machine interface technologies, laying a core foundation for breakthroughs in this field [3]. Group 3: Pricing and Valuation - The acquisition was made at a stage when the target companies are still in the business incubation phase, allowing for a valuation that reflects the actual asset value and avoids potential overvaluation during commercial maturity [4]. - The assessed value of the target companies is 158 million yuan for Sanjian Qifa and 207.7 million yuan for Xufeng, with a dynamic price-to-sales ratio around 3, significantly lower than industry peers [4]. - Performance commitments from the sellers include a cumulative net profit of no less than 50.1 million yuan for Sanjian Qifa from 2026 to 2028 and 82.8 million yuan for Xufeng from 2028 to 2030, with cash compensation mechanisms in place for unmet targets [4][5]. Group 4: Market Impact - The acquisition is expected to enhance the company's long-term profitability and industry influence, with potential for revenue synergies and commercial realization in cutting-edge sectors [7]. - The deal aligns with industry trends towards deep mergers and acquisitions, positioning the company competitively within the global life sciences and gene sequencing markets [7].